When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

Ancillary Cannabis Stocks Perform Best Again

As we described in a previous article, the Global Cannabis Stock Index moved lower in August, falling 7.5%. It is now up 4.1% in 2024. In this article,

August 31, 2024

Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 – Biotech Investments

Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 13-Nov-2024 /

November 14, 2024

Healthcare Embraces Generative AI: 70% of Organizations Actively Explore its Revenue Cycle Potential

What You Should Know: – AKASA, a leading developer of AI-powered automation for the revenue cycle, released new survey results showing that more than 70

November 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.